New technique of cellular vaccination against HIV

Scientists at The Scripps Research Institute have found a way to tether HIV-fighting antibodies to immune cells, creating a cell population resistant to the virus. Researchers have used membrane-tethered, receptor blocking antibodies to achieve this outcome.Here, cells protected from rhinovirus by membrane-tethered, receptor-blocking antibodies survive well and form colonies. Credit: Jia Xie, Lerner lab, The … Continue reading New technique of cellular vaccination against HIV

New approach to Multiple Sclerosis treatment using immunosuppression and stem cells shows promise

New clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS).Five years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of … Continue reading New approach to Multiple Sclerosis treatment using immunosuppression and stem cells shows promise

Animal study shows combination of antibodies are effective in HIV

Without antiretroviral drug treatment, the majority of people infected with HIV ultimately develop AIDS, as the virus changes and evolves beyond the body's ability to control it. But a small group of infected individuals called elite controllers possess immune systems capable of defeating the virus. They accomplish this by manufacturing broadly neutralizing antibodies, which can … Continue reading Animal study shows combination of antibodies are effective in HIV

Multiple Sclerosis medication alemtuzumab can trigger severe B cell mediated brain inflammation

The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects. This was the finding by a team led by Prof Dr Aiden Haghikia and Prof Dr Ralf Gold from the Department of Neurology of the Ruhr-Universität Bochum at St. Josef’s Hospital. In the journal Lancet Neurology, the scientists report on two patients for … Continue reading Multiple Sclerosis medication alemtuzumab can trigger severe B cell mediated brain inflammation

Local chemotherapy delivered directly to the brain preserves immune system for further immunotherapy in mouse models of glioblastoma multiforme

In experiments on mice with a form of aggressive brain cancer, Johns Hopkins researchers have shown that localized chemotherapy delivered directly to the brain rather than given systemically may be the best way to keep the immune system intact and strong when immunotherapy is also part of the treatment. The researchers say their study results, reported … Continue reading Local chemotherapy delivered directly to the brain preserves immune system for further immunotherapy in mouse models of glioblastoma multiforme

Making T-Cell receptor gene therapy safer by domain swapping

The human body produces T cells to recognize and fight disease. Each T cell has a unique T cell receptor (or TCR) on its surface that surveils small fragments of proteins presented by other cells. Upon detecting evidence of cancer or infection, a subset of T cells binds the diseased cells and orchestrates their elimination. … Continue reading Making T-Cell receptor gene therapy safer by domain swapping

HIV treatment with immunotherapy using VRC01 shows promise and limitations

Immunotherapy has revolutionized treatment options in oncology, neurology, and many infectious diseases and now there is fresh hope that the same method could be used to treat or functionally cure HIV, according to two related studies from Perelman School of Medicine at the University of Pennsylvania, the University of Alabama at Birmingham (UAB), and the … Continue reading HIV treatment with immunotherapy using VRC01 shows promise and limitations

Research shows subopitmal reporting of adverse events in targeted therapy and immunotherapy trials

A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and the duration of the adverse events, researchers have told the ESMO 2016 Congress in Copenhagen.“Reporting adverse events from clinical trials with new agents is a crucial point, … Continue reading Research shows subopitmal reporting of adverse events in targeted therapy and immunotherapy trials